Coya Therapeutics Inc. (COYA): Price and Financial Metrics
COYA Price/Volume Stats
| Current price | $8.44 | 52-week high | $10.69 |
| Prev. close | $8.24 | 52-week low | $3.21 |
| Day low | $8.07 | Volume | 30,300 |
| Day high | $8.58 | Avg. volume | 88,335 |
| 50-day MA | $8.99 | Dividend yield | N/A |
| 200-day MA | $6.01 | Market Cap | 123.24M |
COYA Stock Price Chart Interactive Chart >
Latest COYA News From Around the Web
Below are the latest news stories about COYA THERAPEUTICS INC that investors may wish to consider to help them evaluate COYA as an investment opportunity.
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.HOUSTON, December 20, 2023--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced that it has appointed Secretary Wilbur Ross to its board of directors, effective immediately. Coya intends to leverage Secretary Ross’s extensive experience in both the business and investment community to help guide strategic partnering activitie |
David Einhorn's Greenlight Capital Adds Coya Therapeutics to Its PortfolioRenowned investment firm Greenlight Capital, led by David Einhorn (Trades, Portfolio), has recently expanded its investment portfolio with the acquisition of shares in Coya Therapeutics Inc (NASDAQ:COYA). On December 12, 2023, the firm added 810,959 shares to its holdings, reflecting a significant commitment to the biotechnology company. |
David Einhorn's Greenlight Capital Boosts Coya Therapeutics HoldingFirm real-time pick highlight |
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to StockholdersHOUSTON, December 13, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman. |
Coya Therapeutics Announces Closing of $26.5 Million Private PlacementHOUSTON, December 12, 2023--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells ("Tregs"), announced today the closing of the sale of an aggregate of 4,370,382 shares of its common stock at a purchase price of $6.06 per share of common stock, in a private placement priced at-the-market under Nasdaq rules. |
COYA Price Returns
| 1-mo | -15.26% |
| 3-mo | 41.37% |
| 6-mo | 70.16% |
| 1-year | 94.02% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 13.90% |
| 2023 | 56.39% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...